Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno(Dana-Farber Cancer Institute), L. J. Wei(Harvard University), Michael Hughes(Universitat Autònoma de Barcelona), Eisuke Inoue(Dana-Farber/Harvard Cancer Center), Lü Tian(Shandong University), Hicham Skali(Dana-Farber/Harvard Cancer Center), Yoshiaki Uyama(Pharmaceuticals and Medical Devices Agency), Toshio Miyata(Dana-Farber/Harvard Cancer Center), Scott D. Solomon(Brigham and Women's Hospital), Lihui Zhao(University of Shanghai for Science and Technology), Susanna Jacobus(Harvard University), Masahiro Takeuchi(The University of Tokyo), Deborah Schrag(Dana-Farber Brigham Cancer Center), Milton Packer(Dana-Farber/Harvard Cancer Center), Paul Gallo(Novartis (United States)), Brian Claggett(National Heart Lung and Blood Institute)
Cited by 777
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k